Are preoperative inflammatory and nutritional markers important for the prognosis of patients with peritoneal metastasis of colorectal cancer?

doi:10.4251/wjgo.v16.i11.4522

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (116)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

Tables (1-2)

Sum=74

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=36

Publishing Process of This Article

Item

Count

Browse

Download

Sum=4

Nov 15, 2024 (publication date) through Oct 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4522-4527
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4522

Table 1 Summary of the results found in the original article

Parameter	n among 133 patients	Most common age in years	Most common sex	Normal albumin, ≥ 35 g/L	Tumor most prevalent location	Most common histology	Number of patients with CC 0/1¹	Number of patients treated with HIPEC²
High NLR	54 (40.6)	≥ 60 (54.1)	Men	46 (85.1)	Left side of the colon	Adenocarcinoma	30 (55.6)	16 (29.6)
Low NLR	79 (59.4)	≥ 60 (54.1)		53 (67.1)			27 (34.1)	19 (24.1)
Normal Hb	94 (70.7)	< 60 (58.5)		78 (82.9)			49 (52.1)	29 (30.8)
Low Hb	39 (29.3)	≥ 60 (64.1)		21 (53.9)			8 (20.5)	6 (15.3)

Data are n (%).

¹Patients with cytoreduction scores of 0 or 1 were considered eligible for hyperthermal intraperitoneal chemotherapy.

²Among the patients pre-selected for hyperthermal intraperitoneal chemotherapy, only those deemed capable of tolerating the procedure received the treatment.

CC: Cytoreduction; Hb: Hemoglobin; HIPEC: Hyperthermal intraperitoneal chemotherapy; NLR: Neutrophil-to-lymphocyte ratio.

Citation: Sforzin I, Borad M, Uson Junior PLS. Are preoperative inflammatory and nutritional markers important for the prognosis of patients with peritoneal metastasis of colorectal cancer? World J Gastrointest Oncol 2024; 16(11): 4522-4527
URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4522.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4522